Patents by Inventor Jin-ping Li

Jin-ping Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for issuing identity certificate to blockchain node and related apparatus
    Patent number: 12225139
    Abstract: A method and device for issuing an identity certificate to a blockchain node in a blockchain network includes issuing a first identity certificate to a first terminal. a second identity certificate issuance request that is from the first terminal and that is made by using the first identity certificate is received and a second identity certificate is issued to the first terminal, which forwards the second identity certificate to a second terminal. A third identity certificate issuance request that is from the second terminal and that is made by using the second identity certificate is received and a third identity certificate is issued to the second terminal, which forwards the third identity certificate to a third terminal.
    Type: Grant
    Filed: February 15, 2024
    Date of Patent: February 11, 2025
    Assignee: TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED
    Inventors: Mao Cai Li, Zong You Wang, Kai Ban Zhou, Chang Qing Yang, Hu Lan, Li Kong, Jin Song Zhang, Yi Fang Shi, Geng Liang Zhu, Qu Cheng Liu, Qiu Ping Chen
  • Diagnostic and Therapeutic Method
    Publication number: 20150037341
    Abstract: The present invention relates to a method of treating or preventing transthyretin amyloidosis, pharmaceutical composition for use in said treatment or prevention, as well as to a diagnostic method and a kit.
    Type: Application
    Filed: February 21, 2012
    Publication date: February 5, 2015
    Applicant: Plysackaridforskning i Uppsala AB
    Inventors: Ulf Lindahl, Jin-ping Li, Fredrik Noborn
  • Heparanase deficient non-human mammals
    Patent number: 8809620
    Abstract: The invention relates to cells and transgenic non-human mammals having at least one disrupted heparanase allele. The invention further relates to methods of screening therapeutic drug candidates utilizing the heparanase deficient non-human mammals and cells.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: August 19, 2014
    Assignee: Shenzhen Hepalink Pharmaceutical Co., Ltd.
    Inventors: Jin-ping Li, Ulf Lindahl, Israel Vlodavsky, Eyal Zcharia
  • HEPARANASE DEFICIENT NON-HUMAN MAMMALS
    Publication number: 20110154511
    Abstract: The invention relates to cells and transgenic non-human mammals having at least one disrupted heparanase allele. The invention further relates to methods of screening therapeutic drug candidates utilizing the heparanase deficient non-human mammals and cells.
    Type: Application
    Filed: April 9, 2009
    Publication date: June 23, 2011
    Inventors: Jin-ping LI, Ulf Lindahl
  • Glucuronyl C5-Epimerase, DNA encoding the same and uses thereof
    Publication number: 20100261253
    Abstract: The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.
    Type: Application
    Filed: July 8, 2008
    Publication date: October 14, 2010
    Applicants: BioTie Therapies Corp., Inalco S.p.A.
    Inventors: Markku Jalkanen, Kamel El Darwish, Ulf Lindahl, Jin-Ping Li
  • Glucuronyl C5-epimerase, DNA encoding the same and uses thereof
    Patent number: 7399626
    Abstract: The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.
    Type: Grant
    Filed: April 11, 2005
    Date of Patent: July 15, 2008
    Assignees: BioTie Therapies Corp., Inalco S.p.A.
    Inventors: Markku Jalkanen, Kamel El Darwish, Ulf Lindahl, Jin-Ping Li
  • Glucuronyl C5-epimerase, DNA encoding the same and uses thereof
    Publication number: 20050181434
    Abstract: The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.
    Type: Application
    Filed: April 11, 2005
    Publication date: August 18, 2005
    Applicants: BioTie Therapies Corp., Inalco S.p.A.
    Inventors: Markku Jalkanen, Kamel El Darwish, Ulf Lindahl, Jin-ping Li
  • Glucuronyl C5-epimerase, DNA encoding the same and uses thereof
    Patent number: 6887698
    Abstract: The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: May 3, 2005
    Assignees: Biotie Therapies Corp., Inalco S.p.A.
    Inventors: Markku Jalkanen, Kamel El Darwish, Ulf Lindahl, Jin-ping Li
  • Glucuronyl C5-epimerase, DNA encoding the same and uses thereof
    Publication number: 20020127696
    Abstract: The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.
    Type: Application
    Filed: December 7, 2001
    Publication date: September 12, 2002
    Applicant: BioTie Therapies Corp.
    Inventors: Markku Jalkanen, Kamel El Darwish, Ulf Lindahl, Jin-Ping Li